Eleva publishes evidence of immunomodulation and neuroprotection using its Factor H biological therapy in preclinical dry AMD study
Freiburg im Breisgau, Germany, April 15, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the publication of new data on its lead pipeline asset Factor H (CPV-104) in the peer-reviewed Journal of Neuroinflammation. In an established animal model of age-related macular degeneration (AMD), Eleva’s recombinant human Factor H improved two hallmarks of the disease by statistically significantly dampening the inflammatory activity of microglia and Müller cells in the eye and attenuating light-induced retinal degeneration. To review the full publication, please click here
“Our innovative Factor H (CPV-104) program continues to generate positive data underlining its broad potential in both complement-related rare disorders and larger indications that correlate with complement deregulation like dry AMD,” commented Andreas Schaaf, Ph.D., Chief Scientific Officer of Eleva. “The in vivo data published today bode well for the ongoing expansion of the development program into additional indications branching out from our initial focus on C3 Glomerulopathy (C3G).”
Dry AMD is a degenerative disease of the retina that can lead to blindness, primarily affecting elderly patients. The complement system plays a central role in dry AMD, driving chronic inflammation and immune cell-mediated killing of retinal cells. The new study, published in collaboration with the University of Cologne, evaluated the effects of intravitreal injections of Factor H (CPV-104) on disease processes such as retinal degradation following light exposure, and indicators of the inflammatory process, such as microglia morphology, localization and migration patterns that drive disease progression. The results provide insights into the neuroprotective and immunomodulatory potential of a human Factor H’s (CPV-104) treatment, indicating that it may be used to delay or prevent dry AMD disease progression in humans.
The full publication, entitled “Moss-derived human complement factor H modulates retinal immune response and attenuates retinal degeneration” is available on the Journal of Neuroinflammation website.
ABOUT ELEVA
Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company’s aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva’s transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential.
MEDIA CONTACTS
eleva GmbH
Fabienne Zeitter
Director Marketing
pr@elevabiologics.com
Phone: +49 761 470 99 0
Valency Communications
Mario Brkulj
mbrkulj@valencycomms.eu
Phone: +49 160 9352 9951
INVESTOR CONTACT
Cohesion Bureau
Elena Erroba
Giovanni Ca’ Zorzi
giovanni.cazorzi@cohesionbureau.com
Phone: +33 7 84 67 07 27
Back to
